Last updated: 11/07/2018 12:57:47

Immunogenicity and safety of a novel adjuvanted HBV vaccine in healthy volunteers positive for the HLA-DQ2 genotype

Request patient level data
GSK study ID
208129/034
See study documents
Clinicaltrials.gov ID
NCT00697749
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Phase III study to compare immunogenicity, safety and reactogenicity of GSK Biologicals’ novel adjuvanted hepatitis B vaccine adminstered intramuscularly, according to a 0, 6 month schedule, to Engerix™-B 20 mcg administered according to a 0,1,6 month schedule in healthy volunteers positive for the HLA-DQ2 genotype
Trial description: This study compares the immunogenicity and safety of the novel adjuvanted HBV vaccine and Engerix™-B administered to subjects who were positively identified as having the HLA-DQ2 genotype
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Anti-HBs antibody concentrations

Timeframe: At month 7

Secondary outcomes:

Occurrence, intensity and relationship to vaccination of solicited local and general signs and symptoms

Timeframe: During a 4 day follow-up period after each vaccination

Occurrence, intensity and relationship to vaccination of unsolicited symptoms

Timeframe: During a 30 day follow-up period after each vaccination

Occurrence, intensity and relationship to vaccination of serious adverse events (SAEs)

Timeframe: During the study period

Anti-HBs antibody concentrations

Timeframe: Day 0, Month 1, Month 6 and Month 7

Cell mediated immunity

Timeframe: At Months 0 and 7

Interventions:
  • Biological/vaccine: HBV-MPL vaccine 208129
  • Biological/vaccine: Engerix™-B
    • Enrollment:
    230
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Hepatitis B
    Product
    Hepatitis B Vaccine, Recombinant
    Collaborators
    Not applicable
    Study date(s)
    April 1999 to January 2000
    Type
    Interventional
    Phase
    3

    Participation criteria

    Sex
    Female & Male
    Age
    15+ years
    Accepts healthy volunteers
    Yes
    • A male or female ≥ 15 years of age at the time of the first vaccination.
    • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
    • Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
    • Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • A male or female ≥ 15 years of age at the time of the first vaccination.
    • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
    • Written informed consent obtained from the subject/ from the parents or guardians of the subject.
    • Known to be seronegative for anti-HBs-antibodies, anti-HBc-antibodies and/or HBsAg.
    • Positive for the HLA-DQ2 genotype as determined in the previous sero-HBV-069 prevalence study.
    • If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination
    Exclusion criteria:
    • Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
    • Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
    • Previous vaccination against hepatitis B.
    • History of non-response to previous hepatitis B vaccination.
    • Known exposure to hepatitis B within 6 weeks.
    • History of hepatitis B infection.
    • Confirmed human immunodeficiency virus (HIV) infection.
    • A family history of congenital or hereditary immunodeficiency.
    • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
    • Acute disease at the time of enrollment.
    • Hepatomegaly, right upper quadrant abdominal pain or tenderness.
    • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration/ administration during the study period.
    • Pregnant or lactating female

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2000-31-01

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website